Pacific Bio (PACB) Q3 Revenue Misses Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Piper Jaffray Upgrades Pacific Biosciences of California (PACB) to Overweight
October 23, 2015 7:09 AM EDTPiper Jaffray upgraded Pacific Biosciences of California (NASDAQ: PACB) from Neutral to Overweight with a price target of $9.00 (from $7.00).
Analyst William R. Quirk commented, "Pacific Biosciences reported 3Q15 revenue of $13.9M, below our $16.4M estimate and the Street's $15.8M expectations. Ongoing... More
